Comparative Pharmacology
Head-to-head clinical analysis: AMONDYS 45 versus VILTEPSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMONDYS 45 versus VILTEPSO.
AMONDYS 45 vs VILTEPSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amondys 45 (casimersen) is a phosphorodiamidate morpholino oligomer that binds to exon 45 of dystrophin pre-mRNA, excluding it during splicing to restore the mRNA reading frame in Duchenne muscular dystrophy (DMD) patients with amenable mutations. This enables production of internally truncated but functional dystrophin protein.
Antisense oligonucleotide that binds to exon 51 of dystrophin pre-mRNA, excluding it during splicing to restore the reading frame and produce a truncated but functional dystrophin protein in patients with Duchenne muscular dystrophy (DMD) with confirmed mutations amenable to exon 51 skipping.
Intravenous infusion over 35-60 minutes: 30 mg/kg once every 7 days.
30 mg/kg intravenously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 3.6 hours, necessitating frequent dosing (weekly) to maintain therapeutic levels.
The terminal elimination half-life is approximately 3-4 weeks in plasma, reflecting slow clearance due to tissue binding and prolonged intracellular retention. Clinically, this supports weekly intravenous dosing.
Primarily renal, with 100% of the dose excreted as unchanged drug in urine.
Viltepso is primarily eliminated via renal excretion. Approximately 60-70% of the administered dose is excreted unchanged in urine within 24 hours, with minimal biliary/fecal elimination (less than 5%).
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide